Movement Alert｜Jazz Pharmaceuticals PLC Intraday Rise 8.61% in Regular Trading, raised full-year revenue guidance and received an RBC target increase

Market Focus

Nov 04

On November 4, Jazz Pharmaceuticals PLC rose 8.61% in Regular Trading, trading at $233.085 per share, with turnover of $119 million.

The move followed third-quarter results that topped revenue expectations and a higher full-year outlook, alongside an RBC price-target increase to $305 from $296 while maintaining an Outperform rating.

Jazz Pharmaceuticals PLC reported third-quarter revenue of $1.243 billion, up 10% year over year and above the roughly $1.208 billion market expectation. The company lifted full-year revenue guidance to $4.78 billion-$4.85 billion, above the approximately $4.73 billion consensus. Although adjusted EPS was a loss of $3.88, results were heavily affected by about $754 million-$755 million of in-process R&D charges tied to the Actio Biosciences acquisition; excluding that item, non-GAAP EPS was $7.15.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1109213263"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1109213263\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1109213263?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-11-04 00:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109213263","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Jazz Pharmaceuticals PLC Intraday Rise 8.61% in Regular Trading, raised full-year revenue guidance and received an RBC target increase","media":"Market Focus","content":"<p><p>On November 4, Jazz Pharmaceuticals PLC rose 8.61% in Regular Trading, trading at $233.085 per share, with turnover of $119 million.</p><p>The move followed third-quarter results that topped revenue expectations and a higher full-year outlook, alongside an RBC price-target increase to $305 from $296 while maintaining an Outperform rating.</p><p>Jazz Pharmaceuticals PLC reported third-quarter revenue of $1.243 billion, up 10% year over year and above the roughly $1.208 billion market expectation. The company lifted full-year revenue guidance to $4.78 billion-$4.85 billion, above the approximately $4.73 billion consensus. Although adjusted EPS was a loss of $3.88, results were heavily affected by about $754 million-$755 million of in-process R&D charges tied to the Actio Biosciences acquisition; excluding that item, non-GAAP EPS was $7.15.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Jazz Pharmaceuticals PLC Intraday Rise 8.61% in Regular Trading, raised full-year revenue guidance and received an RBC target increase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Jazz Pharmaceuticals PLC Intraday Rise 8.61% in Regular Trading, raised full-year revenue guidance and received an RBC target increase\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-11-04 00:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On November 4, Jazz Pharmaceuticals PLC rose 8.61% in Regular Trading, trading at $233.085 per share, with turnover of $119 million.</p><p>The move followed third-quarter results that topped revenue expectations and a higher full-year outlook, alongside an RBC price-target increase to $305 from $296 while maintaining an Outperform rating.</p><p>Jazz Pharmaceuticals PLC reported third-quarter revenue of $1.243 billion, up 10% year over year and above the roughly $1.208 billion market expectation. The company lifted full-year revenue guidance to $4.78 billion-$4.85 billion, above the approximately $4.73 billion consensus. Although adjusted EPS was a loss of $3.88, results were heavily affected by about $754 million-$755 million of in-process R&D charges tied to the Actio Biosciences acquisition; excluding that item, non-GAAP EPS was $7.15.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JAZZ","symbol_name":"爵士制药","start_time":0,"source_url":"","article_id":"1109213263","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109213263","pubTimestamp":1793722440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On November 4, Jazz Pharmaceuticals PLC rose 8.61% in Regular Trading, trading at $233.085 per share, with turnover of $119 million.The move followed third-quarter results that topped revenue...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"JAZZ":"爵士制药"},"translate_title":"走势提醒|Jazz Pharmaceuticals PLC 常规交易盘中上涨 8.61%，上调全年收入指引并获得 RBC 目标上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JAZZ":1},"content_text":"On November 4, Jazz Pharmaceuticals PLC rose 8.61% in Regular Trading, trading at $233.085 per share, with turnover of $119 million.The move followed third-quarter results that topped revenue expectations and a higher full-year outlook, alongside an RBC price-target increase to $305 from $296 while maintaining an Outperform rating.Jazz Pharmaceuticals PLC reported third-quarter revenue of $1.243 billion, up 10% year over year and above the roughly $1.208 billion market expectation. The company lifted full-year revenue guidance to $4.78 billion-$4.85 billion, above the approximately $4.73 billion consensus. Although adjusted EPS was a loss of $3.88, results were heavily affected by about $754 million-$755 million of in-process R&D charges tied to the Actio Biosciences acquisition; excluding that item, non-GAAP EPS was $7.15.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}